Results 151 to 160 of about 1,966,627 (313)

Conceptualizing Kirchnerismo

Partecipazione e Conflitto, 2017
Fil: Peruzzotti, Carlos Enrique. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina.
openaire   +3 more sources

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

A next generation of the schema therapy model of personality pathology: A cross-cultural and international study protocol. [PDF]

PLoS One
Mamali FC, Rijkeboer M, Molenaar D, Rameckers SA, Panzeri M, Arntz A, Lee CW, Brockman R, Ho Tan D, Mozumder MK, Gayen TK, Dyakov D, Stabrouskaya Y, Gatam A, Lobanovich V, Kanavina S, Romanovich V, Andreevich OA, Tkhoryk N, Shabaikovich A, Dierckx E, Pauwels E, Eggermont K, Matos FR, Puléo Barela R, Frossard LQ, Lazarova IS, Peneva K, Katrandjieva A, St Lazarova A, Zhu Y, Lyu B, Liu Y, Li L, Qin H, Guo X, Hu X, Zhang S, Ma OYT, Tang ALY, Moeller SB, Arendt ITP, Bach B, Meline J, Tapia G, M'bailara K, Abdushelishvili K, Begiashvili A, Badrishvili N, Gvinianidze A, Akopashvili L, Khabazi I, Kopf-Beck J, Leithne C, Renner F, Egli S, Quaatz SM, Malogiannis IA, Giannoulis E, Simos G, Unoka Z, Simon L, Simon V, Munivenkatappa M, Sudhir PM, Kohli TK, Shrivastava A, Misra AA, Khanna A, Louis JP, Santoso NM, Shanti TI, Witarso LS, Hedayati M, Samimi A, Malekasgar S, Basile B, Krone I, Orupe A, Gecaite-Stonciene J, Pociunaite J, Renee Tan HJ, Chan E, Heimkumar V, Kadri N, Karroumi S, Chentaf FZ, Ezzahiri N, Rachidi H, Bouchebti S, Bouidar H, Hikmat W, Chroukate F, Ennaciri Z, Thimm JC, Lorentzen V, Michałowski JM, Popiel AE, Mącik D, Browarczyk WM, Céu Salvador MD, Păduraru AE, Semeniuc SE, Stroian PI, Șubredu I, Yaltonskaya A, Maryasova D, Titova O, Gegel N, Gorodentseva N, Skryabina M, Plichko A, Pavlova O, Prokaeva S, Malashchanka V, Michelle Neo HL, Stein DJ, Hawa W, Hartmann JP, Lee E, Song Y, Gómez-Juanes R, Calvete E, Cid J, Schmidt RE, Homan S, Sakulsriprasert C, Phukao D, Thawornwutichat R, Mamoon W, Chandraungs A, Supreeyaporn N, Bachrach N, Keulen-de Vos M, Lobbestael J, Dorrestijn E, Krans J, Yakin D, Baştak D, Taşlioğlu Sayiner AC, İnce B, Tasilaridis S, Ergelen M, Kennedy FC, Taylor CDJ, First MB, Lockwood G, Appenzeller Z, Norton AR, Seeley-Wait E, Abbott MJ, Allen KL, Hasan S, Morales Hernández SA, Sharaf AM, Ruths FA.   +155 more
europepmc   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

Conceptualization in HRM Research and Conceptualization of HRM Research: A Simplified Conceptual Study

Doing research has become a valuable duty of academics, a mandatory requirement to be met by the students pursuing Bachelor’s Honours Degrees, Research Master’s Degrees, and Doctoral Degrees, and an emerging responsibility, if not a duty, for ...
H. H. D. N. P. Opatha
core   +1 more source

Comparing risk factors in severe COVID-19 using machine learning and non-machine learning methods: analysis from 2 international randomized controlled trials. [PDF]

JAMIA Open
Møller Jensen C, Zargari Marandi R, Moestrup KS, Mourad A, Mena Lora AJ, Sherman BT, Vock DM, Nordwall JA, Carson JM, Peiffer-Smadja N, Aggarwal NR, Naiman NE, Brown SM, Barrett TW, Hatlen T, Kjærgaard VS, Chang W, Sydes MR, Lundgren J, Jensen TO, STRIVE Network and ITAC and TICO Study Groups .   +20 more
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source